{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T03:35:16Z","timestamp":1764646516995},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiologie"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00117-024-01340-x","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T22:01:42Z","timestamp":1719957702000},"page":"643-652","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interstitielle Lungenerkrankungen","Interstitial lung diseases"],"prefix":"10.1007","volume":"64","author":[{"given":"D.","family":"Soriano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Nattenm\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Schygulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Jouanjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Venhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Jandova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Stolz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. C.","family":"Frye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"issue":"05","key":"1340_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1055\/a-2017-8971","volume":"77","author":"M Kreuter","year":"2023","unstructured":"Kreuter\u00a0M, Behr\u00a0J, Bonella\u00a0F, Costabel\u00a0U, Gerber\u00a0A, Hamer\u00a0OW et\u00a0al (2023) S1-Leitlinie Interdisziplin\u00e4re Diagnostik interstitieller Lungenerkrankungen im Erwachsenenalter. Pneumologie 77(05):269\u2013302","journal-title":"Pneumologie"},{"issue":"4","key":"1340_CR2","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1378\/chest.124.4.1215","volume":"124","author":"GW Hunninghake","year":"2003","unstructured":"Hunninghake\u00a0GW, Lynch\u00a0DA, Galvin\u00a0JR, Gross\u00a0BH, M\u00fcller\u00a0N, Schwartz\u00a0DA et\u00a0al (2003) Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest 124(4):1215\u20131223","journal-title":"Chest"},{"issue":"5","key":"1340_CR3","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu\u00a0G, Remy-Jardin\u00a0M, Myers\u00a0JL, Richeldi\u00a0L, Ryerson\u00a0CJ, Lederer\u00a0DJ et\u00a0al (2018) Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med 198(5):e44\u201368","journal-title":"Am J Respir Crit Care Med"},{"issue":"165","key":"1340_CR4","doi-asserted-by":"publisher","first-page":"220003","DOI":"10.1183\/16000617.0003-2022","volume":"31","author":"V Cottin","year":"2022","unstructured":"Cottin\u00a0V, Martinez\u00a0FJ, Smith\u00a0V, Walsh\u00a0SLF (2022) Multidisciplinary teams in the clinical care of fibrotic interstitial lung disease: current perspectives. Eur Respir Rev 31(165):220003","journal-title":"Eur Respir Rev"},{"key":"1340_CR5","volume-title":"Diagnostic criteria for idiopathic pulmonary fibrosis: a\u00a0Fleischner Society White Paper. 153","author":"DA Lynch","year":"2017","unstructured":"Lynch\u00a0DA, Sverzellati\u00a0N, Travis\u00a0WD, Brown\u00a0KK, Colby\u00a0TV, Galvin\u00a0JR et\u00a0al (2017) Diagnostic criteria for idiopathic pulmonary fibrosis: a\u00a0Fleischner Society White Paper. 153"},{"issue":"6","key":"1340_CR6","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1183\/09031936.00092309","volume":"35","author":"EJ Kim","year":"2010","unstructured":"Kim\u00a0EJ, Elicker\u00a0BM, Maldonado\u00a0F, Webb\u00a0WR, Ryu\u00a0JH, Van Uden\u00a0JH et\u00a0al (2010) Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir\u00a0J 35(6):1322\u20131328","journal-title":"Eur Respir J"},{"issue":"2","key":"1340_CR7","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s00292-018-0503-1","volume":"39","author":"F L\u00e4nger","year":"2018","unstructured":"L\u00e4nger\u00a0F, Stark\u00a0H, Braubach\u00a0P, Ackermann\u00a0M, Hussein\u00a0K, Teiken\u00a0K et\u00a0al (2018) Sch\u00e4digungsmuster interstitieller Lungenerkrankungen. Pathologie 39(2):262\u2013271","journal-title":"Pathologie"},{"issue":"5","key":"1340_CR8","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1378\/chest.116.5.1168","volume":"116","author":"G Raghu","year":"1999","unstructured":"Raghu\u00a0G, Mageto\u00a0YN, Lockhart\u00a0D, Schmidt\u00a0RA, Wood\u00a0DE, Godwin\u00a0JD (1999) The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: a\u00a0prospective study. Chest 116(5):1168\u20131174","journal-title":"Chest"},{"issue":"4","key":"1340_CR9","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1164\/rccm.202206-1041ST","volume":"206","author":"V Cottin","year":"2022","unstructured":"Cottin\u00a0V, Selman\u00a0M, Inoue\u00a0Y, Wong\u00a0AW, Corte\u00a0TJ, Flaherty\u00a0KR et\u00a0al (2022) Syndrome of Combined Pulmonary Fibrosis and Emphysema: An official research statement from American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and Asociaci\u00f3n Latinoamericana de T\u00f3rax (ALAT). Am J Respir Crit Care Med 206(4):e7\u2013e41","journal-title":"Am J Respir Crit Care Med"},{"issue":"21","key":"1340_CR10","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","volume":"366","author":"G Raghu","year":"2012","unstructured":"Raghu\u00a0G, Anstrom\u00a0KJ, King\u00a0TE, Lasky\u00a0JA, Martinez\u00a0FJ, Idiopathic Pulmonary Fibrosis Clinical Research Network (2012) Prednisone, azathioprine, and N\u2011acetylcysteine for pulmonary fibrosis. N\u00a0Engl J Med 366(21):1968\u20131977","journal-title":"N Engl J Med"},{"key":"1340_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","volume":"113","author":"L Richeldi","year":"2016","unstructured":"Richeldi\u00a0L, Cottin\u00a0V, du Bois\u00a0RM, Selman\u00a0M, Kimura\u00a0T, Bailes\u00a0Z et\u00a0al (2016) Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS\u00ae trials. Respir Med 113:74\u201379","journal-title":"Respir Med"},{"issue":"9779","key":"1340_CR12","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble\u00a0PW, Albera\u00a0C, Bradford\u00a0WZ, Costabel\u00a0U, Glassberg\u00a0MK, Kardatzke\u00a0D et\u00a0al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377(9779):1760\u20131769","journal-title":"Lancet"},{"issue":"22","key":"1340_CR13","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King","year":"2014","unstructured":"King\u00a0TE, Bradford\u00a0WZ, Castro-Bernardini\u00a0S, Fagan\u00a0EA, Glaspole\u00a0I, Glassberg\u00a0MK et\u00a0al (2014) A\u00a0phase\u00a03\u00a0trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N\u00a0Engl J Med 370(22):2083\u20132092","journal-title":"N Engl J Med"},{"issue":"1","key":"1340_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2397198320915042","volume":"6","author":"ER Volkmann","year":"2021","unstructured":"Volkmann\u00a0ER, Fischer\u00a0A (2021) Update on morbidity and mortality in systemic sclerosis\u2013related interstitial lung disease. J\u00a0Scleroderma Relat Disord 6(1):11\u201320","journal-title":"J Scleroderma Relat Disord"},{"issue":"26","key":"1340_CR15","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler\u00a0O, Highland\u00a0KB, Gahlemann\u00a0M, Azuma\u00a0A, Fischer\u00a0A, Mayes\u00a0MD et\u00a0al (2019) Nintedanib for systemic sclerosis-associated interstitial lung disease. N\u00a0Engl J Med 380(26):2518\u20132528","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"1340_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00393-020-00946-5","volume":"80","author":"S Ewig","year":"2021","unstructured":"Ewig\u00a0S, Bollow\u00a0M (2021) Lungenmanifestationen bei adulten rheumatischen Erkrankungen. Z\u00a0Rheumatol 80(Suppl 1):13\u201332","journal-title":"Z Rheumatol"},{"issue":"4","key":"1340_CR17","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3390\/jcm9041082","volume":"9","author":"G Cassone","year":"2020","unstructured":"Cassone\u00a0G, Manfredi\u00a0A, Vacchi\u00a0C, Luppi\u00a0F, Coppi\u00a0F, Salvarani\u00a0C et\u00a0al (2020) Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows. J\u00a0Clin Med 9(4):1082","journal-title":"J Clin Med"},{"issue":"18","key":"1340_CR18","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty\u00a0KR, Wells\u00a0AU, Cottin\u00a0V, Devaraj\u00a0A, Walsh\u00a0SLF, Inoue\u00a0Y et\u00a0al (2019) Nintedanib in progressive fibrosing interstitial lung diseases. N\u00a0Engl J Med 381(18):1718\u20131727","journal-title":"N Engl J Med"},{"issue":"5","key":"1340_CR19","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","volume":"9","author":"J Behr","year":"2021","unstructured":"Behr\u00a0J, Prasse\u00a0A, Kreuter\u00a0M, Johow\u00a0J, Rabe\u00a0KF, Bonella\u00a0F et\u00a0al (2021) Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a\u00a0double-blind, randomised, placebo-controlled, phase\u00a02b\u00a0trial. Lancet Respir Med 9(5):476\u2013486","journal-title":"Lancet Respir Med"},{"issue":"9","key":"1340_CR20","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu\u00a0G, Remy-Jardin\u00a0M, Richeldi\u00a0L, Thomson\u00a0CC, Inoue\u00a0Y, Johkoh\u00a0T et\u00a0al (2022) Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med 205(9):e18\u2013e47","journal-title":"Am J Respir Crit Care Med"},{"key":"1340_CR21","first-page":"94","volume-title":"Pharmakotherapie der idiopathischen Lungenfibrose (ein Update) und anderer progredienter pulmonaler Fibrosen: S2k-Leitline der Deutsche Gesellschaft f\u00fcr Pneumologie und Beatmungsmedizin e.\u202fV. Pneumologie","author":"J Behr","year":"2023","unstructured":"Behr\u00a0J, Bonella\u00a0F, Frye\u00a0BC, G\u00fcnther\u00a0A, Hagmeyer\u00a0L, Henes\u00a0J et\u00a0al (2023) Pharmakotherapie der idiopathischen Lungenfibrose (ein Update) und anderer progredienter pulmonaler Fibrosen: S2k-Leitline der Deutsche Gesellschaft f\u00fcr Pneumologie und Beatmungsmedizin e.\u202fV. Pneumologie, S\u00a094\u2013119"},{"key":"1340_CR22","doi-asserted-by":"crossref","unstructured":"Pugashetti JV, Adegunsoye A, Wu Z, Lee CT, Srikrishnan A, Ghodrati S et\u00a0al Validation of proposed criteria for progressive pulmonary fibrosis. Am J Respir Crit Care Med 207(1):69\u201376","DOI":"10.1164\/rccm.202201-0124OC"},{"key":"1340_CR23","doi-asserted-by":"crossref","unstructured":"Mankikian J, Caille A, Reynaud-Gaubert M, Agier MS, Bermudez J, Bonniaud P et\u00a0al (2023) Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a\u00a0double-blind, randomised, placebo-controlled trial. Eur Respir\u00a0J","DOI":"10.1183\/13993003.02071-2022"},{"issue":"140","key":"1340_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1183\/16000617.0011-2016","volume":"25","author":"T Flament","year":"2016","unstructured":"Flament\u00a0T, Bigot\u00a0A, Chaigne\u00a0B, Henique\u00a0H, Diot\u00a0E, Marchand-Adam\u00a0S (2016) Pulmonary manifestations of Sj\u00f6gren\u2019s syndrome. Eur Respir Rev 25(140):110\u2013123","journal-title":"Eur Respir Rev"},{"issue":"6","key":"1340_CR25","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis\u00a0WD, Costabel\u00a0U, Hansell\u00a0DM, King\u00a0TE, Lynch\u00a0DA, Nicholson\u00a0AG et\u00a0al (2013) An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial Pneumonias. Am J Respir Crit Care Med 188(6):733\u2013748","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"1340_CR26","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1164\/rccm.202005-2032ST","volume":"202","author":"G Raghu","year":"2020","unstructured":"Raghu\u00a0G, Remy-Jardin\u00a0M, Ryerson\u00a0CJ, Myers\u00a0JL, Kreuter\u00a0M, Vasakova\u00a0M et\u00a0al (2020) Diagnosis of hypersensitivity pneumonitis in adults: an official ATS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med 202(3):e36\u201369","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1340_CR27","doi-asserted-by":"publisher","first-page":"1900531","DOI":"10.1183\/13993003.00531-2019","volume":"54","author":"J Barnett","year":"2019","unstructured":"Barnett\u00a0J, Molyneaux\u00a0PL, Rawal\u00a0B, Abdullah\u00a0R, Hare\u00a0SS, Vancheeswaran\u00a0R et\u00a0al (2019) Variable utility of mosaic attenuation to distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis. Eur Respir\u00a0J 54(1):1900531","journal-title":"Eur Respir J"},{"key":"1340_CR28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01983-2019","author":"LJD Sadeleer","year":"2020","unstructured":"Sadeleer\u00a0LJD, Hermans\u00a0F, Dycker\u00a0ED, Yserbyt\u00a0J, Verschakelen\u00a0JA, Verbeken\u00a0EK et\u00a0al (2020) Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in fibrotic hypersensitivity pneumonitis: a\u00a0retrospective cohort study. Eur Respir\u00a0J. https:\/\/doi.org\/10.1183\/13993003.01983-2019","journal-title":"Eur Respir J"},{"issue":"7","key":"1340_CR29","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S2213-2600(20)30168-5","volume":"8","author":"H Hatabu","year":"2020","unstructured":"Hatabu\u00a0H, Hunninghake\u00a0GM, Richeldi\u00a0L, Brown\u00a0KK, Wells\u00a0AU, Remy-Jardin\u00a0M et\u00a0al (2020) Interstitial lung abnormalities detected incidentally on CT: a\u00a0position paper from the Fleischner Society. Lancet Respir Med 8(7):726\u2013737","journal-title":"Lancet Respir Med"}],"container-title":["Die Radiologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-024-01340-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00117-024-01340-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-024-01340-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T13:08:29Z","timestamp":1722258509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00117-024-01340-x"}},"subtitle":["Vom Bild zur Therapie","From imaging to treatment"],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1340"],"URL":"https:\/\/doi.org\/10.1007\/s00117-024-01340-x","relation":{},"ISSN":["2731-7048","2731-7056"],"issn-type":[{"type":"print","value":"2731-7048"},{"type":"electronic","value":"2731-7056"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"10 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"D.\u00a0Soriano gibt an, dass Vortragshonorare von Boehringer Ingelheim und Reisekostenerstattung von Chiesi bestehen. E.\u00a0Schygulla, L.\u00a0Jouanjan und N.\u00a0Venhoff geben an, dass Vortragshonorare und Reisekostenerstattung von Boehringer Ingelheim bestehen. I.\u00a0Jandova gibt Vortragshonorare von Boehringer Ingelheim an. D.\u00a0Stolz gibt an, dass Beratert\u00e4tigkeit und Vortragshonorare von AstraZeneca AG, Novartis AG, GSK AG, Roche AG, Zambon, Pfizer, Schwabe Pharma AG, Vifor AG, Chiesi AG, MSD, Sanofi, Chemie Menarini, CSL Behring und Boehringer Ingelheim bestehen. B.C.\u00a0Frye gibt an, dass Beratert\u00e4tigkeit f\u00fcr Advita Lifescience GmbH und Boehringer Ingelheim bestehen, Vortragshonorare von Actelion, AstraZeneca, Boeringer Ingelheim, Novartis, Roche und Vifor, sowie Forschungsunterst\u00fctzung von Bristol-Myers Squibb und Relief Therapeutics bestehen. J.\u00a0Nattenm\u00fcller und K.\u00a0Schr\u00f6der geben an, dass kein Interessenskonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}